Condition: Endometrial Cancer · Sponsor: Kartos Therapeutics, Inc.
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses of navtemadlin alongside an observational control arm to determine the Phase 3 navtemadlin dose. Part 2 will evaluate the efficacy and safety of navtemadlin Phase 3 dose compared to placebo.
This description comes directly from the study's public registry record.
John Mei · 650-542-0136 · jmei@kartosthera.com
Always discuss trial participation with your own doctor first.
| Kaiser Permanente Center | Vallejo, California, United States | Recruiting |
| Northside Hospital | Atlanta, Georgia, United States | Recruiting |
| St. Joseph | Savannah, Georgia, United States | Recruiting |
| Dr. Sudarshan K. Sharma, Ltd. | Hinsdale, Illinois, United States | Recruiting |
| Parkview Research Center | Fort Wayne, Indiana, United States | Recruiting |
| Indiana University | Indianapolis, Indiana, United States | Recruiting |
| Maryland Oncology Hematology, P.A. | Silver Spring, Maryland, United States | Recruiting |
| Minnesota Oncology Hematology, P.A. | Minneapolis, Minnesota, United States | Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| Women's Cancer Center of Nevada | Las Vegas, Nevada, United States | Recruiting |
| Good Samaritan Hospital Medical Center | West Islip, New York, United States | Recruiting |
| FirstHealth Carolinas | Pinehurst, North Carolina, United States | Recruiting |
+ 71 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05797831